1. U.S. NDA accepted for priority review of mavorixafor in WHIM syndrome
2. PDUFA date of April 30, 2024: PRV2 eligible if approved for WHIM;
3. Additional Phase 2 CN trial data expected in 1H 2024
4. 现金1.42亿，负债1亿；市值1.6亿；
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
1. U.S. NDA accepted for priority review of mavorixafor in WHIM syndrome
2. PDUFA date of April 30, 2024: PRV2 eligible if approved for WHIM;
3. Additional Phase 2 CN trial data expected in 1H 2024
4. 现金1.42亿，负债1亿；市值1.6亿；